Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (Q38601785)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 August 2017

Language	Label	Description	Also known as
English	Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial	scientific article published on 25 August 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1 reference

based on heuristic

inferred from title

atherosclerosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Peter Libby

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1

object named as

Paul M Ridker

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

6

object named as

Robert J Glynn

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1 reference

ORCID Public Data File 2021

Jean G MacFadyen

2

object named as

Jean G MacFadyen

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

3

object named as

Tom Thuren

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

CANTOS Trial Group

7

object named as

CANTOS Trial Group

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

author name string

Brendan M Everett

4

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

language of work or name

0 references

publication date

25 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunity, Inflammation, and Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular and molecular pathways linking inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer-related inflammation: common themes and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The Role of Inflammation in the Pathogenesis of Non-small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-1 is required for tumor invasiveness and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Why not treat human cancer with interleukin-1 blockade?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

C-reactive protein and risk of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation and cancer: back to Virchow?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of interleukin 1 beta (IL-1β) polymorphism with mRNA expression and risk of non small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932247-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)32247-X

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38601785&oldid=1769737701"